Experiences with
Chronic fatigue syndrome (CFS)Related links
Myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS)

HealthUnlocked contains information from NHS Digital, licensed under the current version of the Open Government Licence
7,798 public posts
Tuesday's Tip
[i] fatigue syndrome (CFS) is one condition that cannot co-exist with PBC. CFS is always its own diagnosis, meaning it's reached only after all other possible conditions for the fatigue have been explored.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease
[/u]
[i]Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease[/i]
[i]Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic, debilitating disease characterised by a wide range of symptoms that severely impact all aspects of life.
Want to take advantage of all our features? Just log in!
or
2025 Update about Chronic Lymphocytic Leukemia, its epidemiology, pathogenesis, diagnosis and therapy
The American Journal of Hematology has published German CLL specialist Michael Hallek's 2025 update about CLL, its epidemiology, pathogenesis, diagnosis and therapy.
[i]"[/i][i]ABSTRACT[/i]
[i]Disease Overview[/i]
[i]Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia
Financial Assistance for Patients with Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL)
Financial Assistance for Patients with Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL) https://www.lls.org/support-resources/financial-support/co-pay-assistance-program
If you are diagnosed with CLL or SLL, you may qualify for The Leukemia & Lymphoma Society's Co-Pay Assistance
Chemo-free treatment with acalabrutinib can benefit CLL/SLL patients never treated before: a plain language summary of the ELEVATE-TN study
The ELEVATE-TN international study commenced in September 2015. The plain language article illustrates how this clinical trial was established and run to determine whether targeted therapy arms using acalabrutinib, a Bruton's Tyrosine Kinase inhibitor ( BTKi), with or without obinutuzumab, would outperform
Improving Treatment Options for Patients with Double Refractory CLL - patients who progressed after treatment with both cBTKis and BCL2i
[i] Abstract[/i]
[i][/i]
[i]The proliferation and survival of chronic lymphocytic leukemia (CLL) cells are heavily dependent on B-cell receptor (BCR) signaling and resistance to apoptosis. Approvals of multiple covalent Bruton's tyrosine kinas inhibitors (cBTKis) as well as the B-cell lymphoma